Aldeyra Therapeutics Inc (NASDAQ:ALDX)

11.29
Delayed Data
As of Apr 16
 -0.28 / -2.42%
Today’s Change
2.50
Today|||52-Week Range
14.62
+64.58%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$535.3M

Company Description

Aldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Contact Information

Aldeyra Therapeutics, Inc.
131 Hartwell Avenue
Lexington Massachusetts 02421
P:(781) 761-4904
Investor Relations:

Employees

Shareholders

Other institutional36.25%
Individual stakeholders28.14%
Mutual fund holders16.99%

Top Executives

Todd C. BradyPresident, Chief Executive Officer & Director
Joshua ReedChief Financial Officer
Bruce GreenbergVice President & Controller
David McMullinChief Commercial Officer
James A. GowSenior Vice President-Clinical Development